Phio Pharmaceuticals Corp Stock Today

PHIO Stock  USD 0.69  0.02  2.82%   


0 of 100

Very Weak

Odds Of Distress

Less than 10

Phio Pharmaceuticals is selling at 0.69 as of the 22nd of June 2024; that is -2.82 percent decrease since the beginning of the trading day. The stock's open price was 0.71. Phio Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Phio Pharmaceuticals Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of May 2024 and ending today, the 22nd of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
10th of May 2012
Health Care
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Phio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 4.59 M outstanding shares of which 177.07 K shares are at this time shorted by private and institutional investors with about 0.38 trading days to cover. More on Phio Pharmaceuticals Corp

Moving against Phio Stock

  0.39XFOR X4 Pharmaceuticals Buyout TrendPairCorr
  0.36FLGC Flora Growth CorpPairCorr

Phio Stock Highlights

ChairmanRobert Bitterman
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00290.003
Notably Down
Slightly volatile
Total Current Liabilities2.2 M1.6 M
Significantly Up
Slightly volatile
Total Assets12.4 M9.4 M
Significantly Up
Slightly volatile
Total Current Assets12.1 M9.3 M
Significantly Up
Slightly volatile
Phio Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Phio Pharmaceuticals' financial leverage. It provides some insight into what part of Phio Pharmaceuticals' total assets is financed by creditors.
Phio Pharmaceuticals Corp currently holds 35 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Phio Pharmaceuticals Corp has a current ratio of 6.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Phio Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.


Phio Pharmaceuticals Corp (PHIO) is traded on NASDAQ Exchange in USA. It is located in 257 Simarano Drive, Marlborough, MA, United States, 01752 and employs 8 people. Phio Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.27 M. Phio Pharmaceuticals Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.59 M outstanding shares of which 177.07 K shares are at this time shorted by private and institutional investors with about 0.38 trading days to cover. Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (10.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Phio Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Roughly 96.0 pct. of Phio Pharmaceuticals outstanding shares are held by general public with 0.49 % owned by insiders and only 3.31 (%) by third-party entities.
Check Phio Ownership Details

Phio Stock Institutional Holders

InstituionRecorded OnShares
Blackrock Inc2024-03-31
Sabby Management Llc2024-03-31
Citigroup Inc2023-12-31
Renaissance Technologies Corp2024-03-31
Morgan Stanley - Brokerage Accounts2024-03-31
Anson Funds Management Lp2024-03-31
Geode Capital Management, Llc2023-12-31
Jpmorgan Chase & Co2023-12-31
Virtu Financial Llc2024-03-31
30.9 K
Cetera Advisors Llc2024-03-31
30.4 K
Cetera Investment Advisers2024-03-31
30.4 K
View Phio Pharmaceuticals Diagnostics

Phio Pharmaceuticals Historical Income Statement

At this time, Phio Pharmaceuticals' Interest Expense is very stable compared to the past year. As of the 22nd of June 2024, Preferred Stock And Other Adjustments is likely to grow to about 3 M, while Depreciation And Amortization is likely to drop about 115.8 K. View More Fundamentals

Phio Stock Against Markets

Phio Pharmaceuticals Corporate Management

Jim CardiaVP OperationsProfile
Caitlin KontulisVP SecretaryProfile
Dr MedScInterim DirectorProfile
Linda MahoneySenior DevelopmentProfile

Additional Information and Resources on Investing in Phio Stock

When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.